Indications

• Persistent dyspeptic symptoms with or without ulceration
  
  
• Duodenal and benign gastric ulceration including that associated with NSAID therapy
  

 

Key Benefits

• Cetidine is a histamine H2-receptor antagonist
  
  
• Rapidly inhibits both basal and stimulated gastric secretion of acid; reduces pepsin output
  
  

Indications

• Treatment of oesophageal reflux disease
  
  
• Treatment of duodenal and benign gastric ulcers including those complicating NSAID therapy
  
  
• Relief of associated dyspeptic symptoms
  
  
• Prophylaxis of acid aspiration
  
  
• Zollinger-Ellison syndrome

* Omeprazole should be used in combination with
antibiotics for eradication of Helicobacter pylori (Hp) in peptic ulcer disease

 

Key Benefits

• Once daily dosing
  
  
• Symptom relief is rapid. In reflux oesophagitis the majority of patients are healed after four weeks.
  
  
• Omizec is now the gold standard in acid suppression owing to its rapid action and reversible proton pump inhibitor
  
  
• Omizec is well tolerated and adverse reactions have generally been mild and reversible
  
  
• Single daily dose and absorption unaffected by food make Omizec convenient for patients
  
  
• Relief of associated dyspeptic symptoms
  
  
• Superior to ranitidine to heal NSAID-induced ulcers and erosions
  
  
• May prevent GI damage in patients requiring long-term NSAID therapy
  
  
• More rapid healing in DU and GU than H2 antagonists
  
  

Key Benefits

• Range of presentations including Ulticer injection for the treatment of duodenal ulcer, benign gastric ulcer and post-operative and stress ulcer
  
  
• Tablets in 150mg and 300mg for once or twice daily dosing